What is the current stock price of Assertio Holdings, Inc. (ASRT)?

As of the latest market data, Assertio Holdings, Inc. (ASRT) is trading at $18.02. The stock has seen a loss of 0.00% today.

Does Assertio Holdings, Inc. (ASRT) pay a dividend?

Based on current data, Assertio Holdings, Inc. does not have a confirmed active dividend policy.

What is the market cap of Assertio Holdings, Inc.?

The current market capitalization of Assertio Holdings, Inc. (ASRT) is approximately unavailable.

ASRT

Assertio Holdings, Inc.·Healthcare

18.02

0.000%(+0.00)

Market Closed

20.99

16.482%(+2.97)

After Hours

Last Updated: — ET

52W L: $8.5552W H: $20.45

ASRT NEWS

prnewswire.com

1d ago

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Assertio Holdings, Inc. (NASDAQ: ASRT)

NEW YORK, April 9, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Assertio Holdings, Inc. (NASDAQ: ASRT ) related to its sale to Garda Therapeutics, Inc. Under the terms of the proposed transaction, Assertio shareholders are expected to receive $18.00 in cash per share plus one contingent value right per share based on certain milestones.

zacks.com

1d ago

Does Assertio (ASRT) Have the Potential to Rally 115.05% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 115.1% in Assertio (ASRT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

businesswire.com

2d ago

Cosette Pharmaceuticals Expands Branded Portfolio through Acquisition of SYMPAZAN® and Additional Products from Assertio

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc., a U.S.-based, branded specialty pharmaceutical company, announced today the closing of a definitive agreement to acquire the U.S. sales and distribution rights for a portfolio of seven branded products from Assertio Holdings, Inc. (Nasdaq: ASRT). The acquisition expands Cosette's branded portfolio and adds the U.S. rights to SYMPAZAN®, a growing, patent-protected asset, further advancing Cosette's disciplined growth strategy. SY.

businesswire.com

2d ago

Assertio Announces Agreement to be Acquired by Garda Therapeutics

LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), today announced a definitive agreement (the “Garda Agreement”) to be acquired by Garda Therapeutics (“Garda” or the “Buyer”) for $18 per share in cash, or a total cash consideration of $125.1 million, (the “Garda Transaction”), plus a contingent value right (the “CVR”). In connection with the Garda Transaction, the Company today also announced that it has signed and closed an agreement (“Co.

benzinga.com

Apr 1

Top 2 Health Care Stocks That May Implode In April

As of April 1, 2026, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

zacks.com

Mar 25

Assertio (ASRT) Surges 17.9%: Is This an Indication of Further Gains?

Assertio (ASRT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Company Profile

Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

IPO Date

1997-12-03

Beta

0.43

Websitewww.assertiotx.com↗